

IMMUNOGEN INC  
Form 8-K  
July 31, 2003

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **JULY 31, 2003**

**ImmunoGen, Inc.**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction  
of incorporation)

**0-17999**  
(Commission  
File Number)

**04-2726691**  
(IRS Employer  
Identification No.)

**128 Sidney Street, Cambridge, MA 02139**  
(Address of principal executive offices) (Zip Code)  
Registrant's telephone number, including area code: **(617) 995-2500**

---

---

---

**ITEM 5. OTHER EVENTS**

On July 31, 2003, ImmunoGen, Inc. announced that the Company signed a collaboration agreement with Aventis to discover, develop and commercialize novel anticancer therapeutics. The press release announcing this event is incorporated herein by reference and filed as Exhibit 99.1 hereto.

**ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS**

(c)  
Exhibits

Exhibit

Exhibit  
No.

---

99.1 The Registrant's Press Release dated July 31, 2003.

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**  
(Registrant)

Date: JULY 31, 2003

/s/ GREGG D. BELOFF

---

Gregg D. Beloff  
Chief Financial Officer and  
Vice President, Finance

3

---

**EXHIBIT INDEX**

Exhibit  
No.      Exhibit

---

99.1 The Registrant's Press Release dated July 31, 2003.

---

QuickLinks

[ITEM 5. OTHER EVENTS](#)

[ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)